Related Experiment Video
Updated: Aug 21, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Anidulafungin: review of a new echinocandin antifungal agent
1University of North Carolina School of Pharmacy, Chapel Hill, NC 27599-7360, USA. ralph_raasch@unc.edu.
Abstract:
Anidulafungin (Vicuron Pharmaceuticals) is a new echinocandin antifungal with potent activity against Aspergillus and Candida spp. Anidulafungin is a noncompetitive inhibitor of (1,3)-beta-D-glucan synthase within fungal cells. The drug is rapidly distributed and steady-state concentrations are achieved after the first dose, when a loading dose of twice the daily maintenance dose is given on day 1. Drug biotransformation occurs via chemical degradation, with no hepatic metabolism or renal elimination. A favorable pharmacokinetic profile and lack of significant drug interactions suggest that patients can receive anidulafungin without dosage adjustments. These characteristics, in addition to comparable efficacy to fluconazole (Diflucan, Pfizer Ltd) in the treatment of esophageal candidiasis, support further investigation of its use in the treatment of systemic fungal infections caused by Candida and Aspergillus spp.
Related Concept Videos
Antifungal Agents
Anthelminthic Agents
Candidiasis
Overview of Fungi
Antimicrobial Effectiveness
Fungal Phylum Microsporidia

